| Basics |
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.
|
| IPO Date: |
November 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.52B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.03 | 2.83%
|
| Avg Daily Range (30 D): |
$0.60 | 2.98%
|
| Avg Daily Range (90 D): |
$0.56 | 2.27%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.06M |
| Avg Daily Volume (30 D): |
2.31M |
| Avg Daily Volume (90 D): |
1.59M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
83 |
| Avg Trade Size (Sh.) (90 D): |
74 |
| Institutional Trades |
| Total Inst.Trades: |
7,352 |
| Avg Inst. Trade: |
$3.31M |
| Avg Inst. Trade (30 D): |
$4.61M |
| Avg Inst. Trade (90 D): |
$5.25M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
4 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.2M |
| Avg Closing Trade (30 D): |
$10.43M |
| Avg Closing Trade (90 D): |
$11.38M |
| Avg Closing Volume: |
171.18K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-1.6
|
$-.29
|
$-1.6
|
|
Diluted EPS
|
$-1.6
|
$-.29
|
$-1.6
|
|
Revenue
|
$ 781.37M
|
$ 212.53M
|
$ 781.37M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -197.88M
|
$ -36.35M
|
$ -197.88M
|
|
Operating Income / Loss
|
$ -164.98M
|
$ -26.16M
|
$ -164.98M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 60.31M
|
$ 14.38M
|
$ 60.31M
|
|
PE Ratio
|
|
|
|
| Splits |
| Mar 19, 2004:
200:1
|
|
